|
Sub-category:
Metastatic Lung Cancer
Category:
Lung Cancer--Metastatic Lung Cancer
Meeting:
2009 ASCO Annual Meeting
Session Type and Session Title:
Oral Presentation, Lung Cancer - Metastatic
Abstract No:
8001
Citation:
J Clin Oncol 27:15s, 2009 (suppl; abstr 8001)
Author(s):
F. Cappuzzo, T. Ciuleanu, L. Stelmakh, S. Cicenas, A. Szczesna, E. Juhasz, E. Esteban Gonzalez, O. Molinier, G. Klingelschmitt, G. Giaccone, on behalf of the SATURN Investigators; Istituto Clinico Humanitas IRCCS, Rozzano, Italy; Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania; Pavlov State Medical University, St. Petersburg, Russian Federation; Institute of Oncology, Vilnius University, Vilnius, Lithuania; Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlic, Otwock, Poland; Koranyi National Institute for Pulmonology, Budapest, Hungary; Hospital Universitario Central de Asturias, Oviedo, Spain; Centre Hospitalier Le Mans, Le Mans, France; F. Hoffmann-La Roche, Basel, Switzerland; CCR, National Cancer Institute, NIH, Bethesda, MD
Abstract:
Background: Erlotinib (E), a small-molecule EGFR TKI, is proven to extend survival versus placebo (P) in 2nd/3rd-line advanced NSCLC. The phase III SATURN study (BO18192) was initiated to evaluate E as maintenance therapy after standard 1st-line platinum-based chemotherapy (CT) in advanced NSCLC. Methods: Patients with no evidence of disease progression after 4 cycles of CT were randomized to receive either E 150 mg/day or P until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) in all patients and the co-primary endpoint was PFS in EGFR immunohistochemistry-positive (IHC+) patients. Results: A total of 1,949 patients entered the CT phase, of whom 889 were randomized to E (n=438) or P (n=451). Median age was 60 years for both arms. Baseline characteristics for E and P arms (%): male/female: 73/27 and 75/25; adenocarcinoma + BAC/squamous-cell/other: 47/38/15 and 44/43/13; stage IIIB/IV: 26/74 and 24/76; Caucasian/Asian/other: 84/14/2 and 83/15/2; ECOG PS 0/1: 31/69 and 32/68; current/former/never smoker: 55/28/18 and 56/27/17. PFS (by investigator assessment; confirmed by independent review) was significantly prolonged with E versus P in all patients (HR 0.71 [95% CI 0.62-0.82]; p<.0001) and in EGFR IHC+ patients (HR 0.69 [95% CI 0.58-0.82]; p<.0001). Subgroup analyses will be reported. Response rate was 12% with E versus 5% with P. Disease control rate (complete response + partial response + stable disease >12 wks) was 40.8% with E versus 27.4% with P (p<.0001). OS data are not yet mature. E was well tolerated: the majority of treatment-related adverse events (AEs) were grade 1/2. AEs reported in ≥10% of all patients were rash (60% with E versus 9% with P) and diarrhea (20% with E versus 5% with P); again, most were grade 1/2. Only 2.3% of patients receiving E had a serious treatment-related AE and 2.8% withdrew due to a treatment-related AE. Conclusions: The SATURN study met its primary and co-primary endpoints with high statistical significance. Erlotinib in the 1st-line maintenance setting is well tolerated, and significantly improves disease control and delays progression versus placebo across patient subgroups.
Abstract Disclosures
Faculty and Discussant Disclosures
Annual Meeting Planning Committee Disclosures
2009 Annual Meeting Proceedings Part I Errata
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy
and are designated with a caret symbol (^) here and in the print version.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by F. Cappuzzo:
Presentations by F. Cappuzzo:
Educational Book Manuscripts by F. Cappuzzo:
|
